Business
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
POTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026, at 1:00 p.m. ET.","length":324,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/3dde6f29c1e882b7268b738bee20ddd8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Qv8ecvL3posrUjjbIbev6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/3dde6f29c1e882b7268b738bee20ddd8","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FbZxTsZmfUOewJOD_N1JJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/3dde6f29c1e882b7268b738bee20ddd8","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/07514a85-2d98-4296-b967-1d0db87b1b65/1136615/png.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"IGC Pharma's management will discuss recent clinical progress in its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease, including enrollment momentum and regulatory developments. The discussion will also cover advancements in the Company's AI-driven precision medicine platform and progress across its broader pipeline of disease-modifying Alzheimer's candidates. Management will provide perspective on upcoming milestones and strategic priorities for fiscal 2026.","length":519,"tagName":"p"},{"type":"text","content":"To register for the fireside chat, please visit: Link","length":53,"tagName":"p"},{"type":"text","content":"About IGC Pharma (dba IGC):","length":27,"tagName":"p"},{"type":"text","content":"IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid ...